Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
December 11 2017 - 8:15AM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
the election of William F. Doyle and Hans Peter Hasler to the Board
of Directors of the Company.
“Bill Doyle and Hans Peter Hasler bring distinguished leadership
backgrounds and complementary sets of expertise to Minerva’s Board
of Directors,” said Dr. Fouzia Laghrissi-Thode, Board member and
chairperson of the search committee at Minerva. “Their
bio-pharma industry-specific experience, which encompasses
strategic development, partnering, licensing, product launches,
marketing and commercialization, will benefit Minerva as the
foundation is laid for the commercialization of the Company’s
products currently in advanced clinical development. We look
forward to Bill’s and Hans’s entrepreneurial and operational
perspectives on how Minerva can best add value beyond its clinical
achievements to help patients suffering from neuropsychiatric
diseases.”
Mr. Doyle is Executive Chairman of Novocure Ltd. (NASDAQ:NVCR),
a commercial stage oncology company pioneering a novel therapy for
solid tumors, where he has served as Chairman of the Board since
2009 and a director since 2004. Mr. Doyle has also been the
Managing Director of WFD Ventures LLC, a private venture capital
firm he co-founded, since 2002. Previously, Mr. Doyle was a
member of Johnson & Johnson’s Medical Devices and Diagnostics
Group Operating Committee and Vice President, Licensing and
Acquisitions. While at Johnson & Johnson, Mr. Doyle was also
Chairman of the Medical Devices Research and Development Council,
Worldwide President of Biosense-Webster, Inc. and a member of the
boards of Cordis Corporation and Johnson & Johnson Development
Corporation, Johnson & Johnson’s venture capital subsidiary.
Earlier in his career, Mr. Doyle was a management consultant in the
global healthcare practice of McKinsey & Company. His
additional board positions include the private company, Blink
Health Ltd., and OptiNose US, Inc. (NASDAQ:OPTN). Mr. Doyle
holds an S.B. in materials science and engineering from the
Massachusetts Institute of Technology and an M.B.A. from Harvard
Business School.
Mr. Hasler is Founder and Chief Executive Officer of Vicarius
Pharma AG, a privately held company that provides strategic options
to non-European bio-pharma companies in bringing late-stage assets
to the European market. He also is a Senior Advisor at SBTech
Global Advisory. His prior corporate experience includes Elan
Corporation, where he was Chief Operating Officer, and Biogen,
Inc., where his positions included Chief Operating Officer,
Executive Vice President, Head of Global Neurology and
International. Previously, Mr. Hasler was at Wyeth
Pharmaceuticals as Senior Vice President, Chief Marketing Officer
and Managing Director of Wyeth Group Germany and General Manager,
Wyeth-Lederle Switzerland, Austria and ECE. Mr. Hasler is Chairman
of the Board of HBM Healthcare Investments AG in Zug, Switzerland
and Director of the Board of Dr. Reddy’s Laboratories in Hyderabad,
India. Mr. Hasler holds a Federal Swiss Commercial Diploma and a
Marketing Manager Certificate from the Swiss Institute of Business
Economy SIB, Zurich, Switzerland.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and major
depressive disorder (MDD); MIN-117, in clinical development for
MDD; and MIN-301, in pre-clinical development for Parkinson’s
disease. Minerva’s common stock is listed on the NASDAQ
Global Market under the symbol “NERV.” For more information,
please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking
statements include statements herein regarding our ability to
successfully develop and commercialize our therapeutic
products. These forward-looking statements are based on our
current expectations and may differ materially from actual results
due to a variety of factors including, without limitation,
management’s ability to successfully achieve its goals; our ability
to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2017, filed
with the Securities and Exchange
Commission on November 6, 2017. Copies of reports
filed with the SEC are posted on our website
at www.minervaneurosciences.com. The forward-looking
statements in this press release are based on information available
to us as of the date hereof, and we disclaim any obligation to
update any forward-looking statements, except as required by
law.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024